netFormulary Central Lancashire Formulary NHS
Lancashire Teaching Hospitals NHS Foundation Trust
Chorley and South Ribble CCG
Greater Preston CCG
 
 Search
 Formulary Chapter 1: Gastro-intestinal system - Full Chapter
01.05.03  Expand sub section  Drugs affecting the immune response
TofactinibBlack Triangle
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
BlueTeq

Xeljanz® 5mg and 10mg tablets

To be used in line with NICE TA547 for moderately to severely active ulcerative colitis

 
Link  NICE TA547
   
Ustekinumab
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
BlueTeq

Stelara For use in line with NICE TA 456 for previously treated moderately to severely active Crohn’s disease in adults.

 
Link  NICE TA 456
   
Adalimumab
(Gastroenterology)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
High Cost Medicine
BlueTeq

Injection 40 mg prefilled pen or prefilled syringe, 40 mg/0.8 ml vial

Should only be used under expert supervision

 
Link  NICE TA187: Crohnís disease - infliximab and adalimumab
Link  NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis
   
Infliximab
(Gastroenterology)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
High Cost Medicine
BlueTeq

Intravenous infusion, powder for reconstitution, 100 mg

Should only be used under expert supervision

 
Link  NICE TA163: Ulcerative colitis (acute manifestations) Infliximab
Link  NICE TA187: Crohns disease - infliximab & adalimumab
Link  NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis
   
Cytotoxic Drug Azathioprine
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Amber 2

Tablets 25 mg, 50 mg

Should only be used under expert supervision

Unlicensed use - IBD

 
Link  Crohn’s disease managment
Link  Shared Care Guideline
Link  Ulcerative Colitis management
   
Golimumab
(Ulcerative Colitis)
View adult BNF View SPC online View childrens BNF  Track Changes
Restricted Drug Restricted
Red
High Cost Medicine
BlueTeq

Injection, Prefilled syringe 90 mg

Should only be used under expert supervision

 
Link  NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis
   
VedolizumabBlack Triangle
(Gastroenterology)
View adult BNF View SPC online  Track Changes
Restricted Drug Restricted
Red
High Cost Medicine
BlueTeq

Concentrate for intravenous infusion, powder for reconstitution 300 mg vials

Should only be used under expert supervision

 
Link  NICE TA352: Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy
Link  NICE TA342: Vedolizumab for treating moderately to severely active ulcerative colitis
   
Ciclosporin
(Gastroenterology)
View adult BNF View SPC online View childrens BNF  Track Changes
Unlicensed Drug Unlicensed
Amber 2

Capsules 25 mg, 50 mg, 100 mg

100 mg/1 ml oral solution

Concentrate for intravenous infusion (oily) 50 mg/1 ml

Should only be used under expert supervision

 
Link  Ciclosporin Shared Care Guideline LMMG
   
Cytotoxic Drug Mercaptopurine
(Gastroenterology)
View adult BNF View SPC online View childrens BNF  Track Changes
Unlicensed Drug Unlicensed
Amber 2

Tablets 50 mg

Should only be used under expert supervision

 
Link  Crohn’s disease management
Link  Mercaptopurine Shared Care Guideline LMMG
Link  Ulcerative Colitis management
   
Cytotoxic Drug Methotrexate
(Gastroenterology)
View adult BNF View SPC online View childrens BNF  Track Changes
Unlicensed Drug Unlicensed
Amber 2

Tablets 2.5 mg

Oral solution 10 mg in 5 ml (Rosemont)

Subcutaneous injection 50 mg/1 ml prefilled pen, 7.5 mg, 10 mg, 12.5 mg, 15 mg, 17.5 mg, 20 mg, 22.5 mg, 25 mg, 27.5 mg, 30 mg (Licensed in Crohn's disease)

Should only be used under expert supervision

The dose is always a weekly dose.

 
Link  Methotrexate Shared Care Guideline LMMG
   
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Amber

Suitable for prescribing in primary care following recommendation or initiation by a specialist. Little or no specific monitoring required. Patient may need a regular review, but this would not exceed that required for other medicines routinely prescribed in primary care. Brief prescribing document or information sheet may be required.  

Amber 1

Suitable for prescribing in primary care following recommendation or initiation by a specialist. Minimal monitoring required. Patient may need a regular review, but this would not exceed that required for other medicines routinely prescribed in primary care. Full prior agreement about patientís on-going care must be reached under the shared care agreement.  

Amber 2

Initiated by specialist and transferred to primary care following a successful initiation period. Significant monitoring required on an on-going basis. Full prior agreement about patientís on-going care must be reached under the shared care agreement. Suitable for enhanced service.  

Black

NOT recommended for use by the NHS in Lancashire. Includes medicines that NICE has not recommended for use and terminated technology appraisals, unless there is a local need.  

Blue

Products shown as blue have different Traffic Light List classifications dependent on indication. See the accompanying text next to the product for further information  

Green

Appropriate for initiation and ongoing prescribing in both primary and secondary care. Generally, little or no routine drug monitoring is required.  

Purple

Low Priority for Prescribing - see Low Priority for Prescribing Policy  

Red

Medicine is supplied by the hospital for the duration of the treatment course. Primary care initiation or continuation of treatment is not recommended unless exceptional circumstances such as specialist GP.  

Red Specialist Centre

Prescribing restricted to Specialist Centres only  

netFormulary